ELISA/assay

KRIBIOLISA™ Alnuctamab ELISA

KBI1752

1 x 96 wells

1050 USD

KRIBIOLISA™ Alnuctamab ELISA

ELISA

1 x 96 wells

1050 USD

ELISA for the detection of Alnuctamab in human serum and plasma. Lead time for this kit is 5 weeks. About the kit: - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life: 1 year.An asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) x CD3 T-cell bispecific monoclonal antibody, Alnuctamab is currently under Phase-1 trial for multiple myeloma.

Human

This ELISA kit comes with a pre-coated plate, concentrated or lyophilized standards, wash solution, subtrate, stop solution and all the required diluents. For the exact contents of the kit, please refer to the datasheet / IFU.

2-8 Deg C

0 ug/ml - 100 ug/ml

7.5 ug/ml

This ELISA employs the quantitative sandwich enzyme immunoassay technique to detect and capture the target bispecific antibody. One target protein to which the bsAb binds is pre-coated onto microwells. Samples and standards are pipetted into microwells and the target bsAb drug present in the sample are bound by the capture antibody. Then, the second target protein to which the bsAb binds wtih HRP (horseradish peroxidase) conjugation is then pipetted and wells are incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of bsAb drug in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Alnuctamab

RUO

2-8 degrees C